Pharming Group N.V. (PHAR)

Market Cap	1.16B +96.9%
Revenue (ttm)	376.13M +26.6%
Net Income	2.85M
EPS	0.00
Shares Out	662.50M
PE Ratio	407.13
Forward PE	42.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,470
Open	17.13
Previous Close	16.64
Day's Range	16.82 - 17.13
52-Week Range	7.50 - 21.34
Beta	0.16
Analysts	Strong Buy
Price Target	39.00 (+130.5%)
Earnings Date	May 7, 2026

About PHAR

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 404
• Stock Exchange: NASDAQ
• Ticker Symbol: PHAR
• Website: https://www.pharming.com

Analyst Summary

According to 2 analysts, the average rating for PHAR stock is "Strong Buy." The 12-month stock price target is $39.0, which is an increase of 130.50% from the latest price.

Price Target

$39.0

(130.50% upside)

Analyst Consensus: Strong Buy